Provided by Tiger Fintech (Singapore) Pte. Ltd.

Urogen Pharma Ltd.

7.37
+2.2343.39%
Post-market: 7.640.2700+3.66%19:59 EDT
Volume:20.72M
Turnover:150.50M
Market Cap:339.81M
PE:-2.42
High:8.25
Open:5.33
Low:5.23
Close:5.14
Loading ...

UroGen Pharma Ltd. Announces Inducement Grants of Restricted Stock Units to New Employees

Reuters
·
06 Jun

Urogen Pharma Ltd : Oppenheimer Cuts Target Price to $10 From $36

THOMSON REUTERS
·
03 Jun

Oppenheimer Remains a Buy on Urogen Pharma (URGN)

TIPRANKS
·
28 May

UroGen Pharma Is Maintained at Buy by Guggenheim

Dow Jones
·
23 May

Urogen Pharma Ltd : Guggenheim Cuts Target Price to $15 From $40

THOMSON REUTERS
·
23 May

UroGen Pharma Shares Fall After HC Wainwright Downgrade

MT Newswires Live
·
23 May

UroGen Pharma Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
22 May

UroGen's FDA Stumble Connected to Trial Concerns -- Market Talk

Dow Jones
·
22 May

BUZZ-UroGen Pharma falls as FDA panel narrowly votes against bladder cancer drug

Reuters
·
22 May

HC Wainwright Downgrades UroGen Pharma to Neutral From Buy

MT Newswires Live
·
22 May

UroGen Pharma Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
22 May

Sector Update: Health Care Stocks Slide Wednesday Afternoon

MT Newswires Live
·
22 May

UroGen Pharma Shares Fall After US FDA Committee Vote on Bladder Cancer Drug

MT Newswires Live
·
22 May

UroGen Pharma down over 50% after resuming trading

TIPRANKS
·
22 May

UroGen Pharma announces outcome of ODAC meeting for UGN-102

TIPRANKS
·
22 May

UroGen Pharma Awaits FDA Decision on UGN-102 for Recurrent Bladder Cancer, Following Narrow ODAC Vote

Reuters
·
22 May

Scotiabank Keeps Their Buy Rating on Urogen Pharma (URGN)

TIPRANKS
·
20 May

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

Dow Jones
·
17 May

UroGen Pharma down after FDA posts UGN-102 briefing documents

TIPRANKS
·
17 May

TD remains confident in approval after UroGen briefing docs

TIPRANKS
·
17 May